Comparing Kaya (OTCMKTS:KAYS) & Biomea Fusion (NASDAQ:BMEA)

Biomea Fusion (NASDAQ:BMEA) and Kaya (OTCMKTS:KAYS) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, risk, institutional ownership, valuation, analyst recommendations and dividends.

Institutional and Insider Ownership

96.7% of Biomea Fusion shares are held by institutional investors. 27.6% of Biomea Fusion shares are held by insiders. Comparatively, 23.5% of Kaya shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares Biomea Fusion and Kaya”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biomea Fusion	N/A	N/A	-$117.25 million	($4.01)	-2.20
Kaya	$200,000.00	3.91	$1.61 million	$0.02	1.77

Kaya has higher revenue and earnings than Biomea Fusion. Biomea Fusion is trading at a lower price-to-earnings ratio than Kaya, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Biomea Fusion and Kaya, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biomea Fusion	0	2	8	2	3.00
Kaya	0	0	0	0	N/A

Biomea Fusion presently has a consensus target price of $30.50, suggesting a potential upside of 245.02%. Given Biomea Fusion’s higher probable upside, research analysts plainly believe Biomea Fusion is more favorable than Kaya.

Profitability

This table compares Biomea Fusion and Kaya’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Biomea Fusion	N/A	-118.90%	-93.66%
Kaya	260.23%	-9.79%	652.87%

Risk and Volatility

Biomea Fusion has a beta of -0.41, meaning that its share price is 141% less volatile than the S&P 500. Comparatively, Kaya has a beta of 0.66, meaning that its share price is 34% less volatile than the S&P 500.

Summary

Kaya beats Biomea Fusion on 8 of the 13 factors compared between the two stocks.

About Biomea Fusion

Biomea Fusion, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, a covalent inhibitor of menin for treating patients with liquid and solid tumors and type 2 diabetes. The company was incorporated in 2017 and is headquartered in Redwood City, California.

About Kaya

Kaya Holdings, Inc., a vertically integrated legal cannabis enterprise, engages in the operation of psychedelic treatment clinics and medical cannabis dispensaries primarily in the United States. It offers a range of cannabis products, including flower, oils, vape cartridges and cannabis infused confections, baked goods, and beverages. The company also operates retail outlets under the Kaya Shack brand name, as well as offers strain specific cannabis cigarettes under the Kaya Buddies name, and strains of cannabis under the Kaya Farms name. In addition, it is involved in the development of a psychedelic treatment center under The Sacred Mushroom name, that provides its guests access to psilocybin treatments, located in Portland, Oregon. The company was formerly known as Alternative Fuels America, Inc. and changed its name to Kaya Holdings, Inc. in April 2015. Kaya Holdings, Inc. is headquartered in Fort Lauderdale, Florida.